HALOZYME THERAPEUTICS INC's ticker is HALO and the CUSIP is 40637H109. A total of 6 filers reported holding HALOZYME THERAPEUTICS INC in Q4 2023. The put-call ratio across all filers is - and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $55,569,807 | +15.0% | 1,454,707 | +8.6% | 0.91% | +21.0% |
| Q2 2023 | $48,302,131 | -3.2% | 1,339,122 | +2.5% | 0.75% | -9.7% |
| Q1 2023 | $49,913,184 | -32.3% | 1,306,970 | +1.0% | 0.84% | -37.5% |
| Q4 2022 | $73,733,544 | +43.6% | 1,294,025 | -0.4% | 1.34% | +37.2% |
| Q3 2022 | $51,360,000 | -10.5% | 1,298,934 | -0.4% | 0.97% | -8.2% |
| Q2 2022 | $57,375,000 | +11.1% | 1,303,983 | +0.7% | 1.06% | +40.3% |
| Q1 2022 | $51,642,000 | +0.8% | 1,294,937 | +1.6% | 0.76% | +14.2% |
| Q4 2021 | $51,255,000 | -0.8% | 1,274,679 | +0.3% | 0.66% | -5.8% |
| Q3 2021 | $51,683,000 | +3.7% | 1,270,480 | +15.7% | 0.70% | +2.9% |
| Q2 2021 | $49,849,000 | +9.3% | 1,097,754 | +0.4% | 0.68% | +3.2% |
| Q1 2021 | $45,590,000 | +9.6% | 1,093,538 | +12.2% | 0.66% | +6.9% |
| Q4 2020 | $41,608,000 | +488.8% | 974,207 | +262.3% | 0.62% | +395.2% |
| Q3 2020 | $7,067,000 | +51.3% | 268,898 | +54.3% | 0.12% | +47.1% |
| Q2 2020 | $4,672,000 | – | 174,275 | – | 0.08% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| TRAN CAPITAL MANAGEMENT, L.P. | 1,084,118 | $61,686,285 | 7.80% |
| SNYDER CAPITAL MANAGEMENT L P | 3,983,814 | $226,679,017 | 5.12% |
| First Light Asset Management, LLC | 923,119 | $52,525,471 | 4.88% |
| Redwood Investments, LLC | 441,809 | $25,138,932 | 3.37% |
| BERNZOTT CAPITAL ADVISORS | 444,728 | $25,305,023 | 3.27% |
| DOHENY ASSET MANAGEMENT /CA | 46,050 | $2,620 | 3.04% |
| Crawford Lake Capital Management, LLC | 42,171 | $2,399,530 | 2.75% |
| 2Xideas AG | 416,586 | $23,703,743 | 2.51% |
| Granite Investment Partners, LLC | 902,882 | $51,373,986 | 2.14% |
| HighMark Wealth Management LLC | 41,790 | $2,377,851 | 1.79% |